Regenxbio Inc. (NASDAQ: RGNX) is a leading biotechnology company headquartered in Rockville, Maryland, specializing in gene therapy using adeno-associated virus (AAV) vectors. Founded in 2009, Regenxbio has established itself as a foundational company in the AAV gene therapy space, providing its proprietary NAV Technology Platform to numerous pharmaceutical and biotechnology partners for the development of treatments for rare genetic diseases, neurodegenerative disorders, and other serious conditions[mendell2015].
The company's NAV Technology Platform represents next-generation AAV delivery systems that offer improved tissue tropism, enhanced payload capacity, and superior manufacturing yields compared to first-generation vectors. This platform has enabled the advancement of multiple gene therapy programs across diverse therapeutic areas[kumar2020].
| Attribute | Value |
|---|---|
| Headquarters | Rockville, Maryland, USA |
| Founded | 2009 |
| Ticker | NASDAQ: RGNX |
| Focus | AAV gene therapy vectors |
| Employees | ~400 (as of 2024) |
| Market Cap | ~$600M (as of 2024) |
Regenxbio operates from a 130,000 square foot GMP manufacturing facility in Rockville, enabling internal production of clinical-grade AAV vectors. The company maintains research facilities in Maryland and has established partnerships with leading academic institutions and pharmaceutical companies worldwide.
Regenxbio's NAV Technology Platform comprises next-generation AAV vectors with enhanced properties for gene delivery:
NAV AAV9: The most widely used serotype for CNS and peripheral nervous system delivery, capable of crossing the blood-brain barrier following systemic administration. AAV9 has demonstrated success in clinical trials for spinal muscular atrophy and is being evaluated for neurodegenerative diseases[hudry2023].
NAV AAV8: Excellent liver transduction capability, making it suitable for metabolic and liver-directed gene therapy applications. AAV8 has been validated in clinical studies for hemophilia and other liver diseases.
NAV AAVrh.10: Alternative serotype for CNS delivery with distinct tropism profiles, useful for targeting specific brain regions or cell populations.
Self-complementary vectors: Enhanced versions that enable more efficient transgene expression through reduced dependency on second-strand synthesis.
The NAV Technology Platform offers several advantages over earlier-generation AAV vectors:
Regenxbio operates primarily through a licensing model, granting pharmaceutical partners access to its NAV Technology Platform for specific therapeutic programs. This approach has generated substantial milestone and royalty revenue while enabling broad application of the technology.
Regenxbio has collaborated with major pharmaceutical companies to develop gene therapies across multiple therapeutic areas:
Regenxbio maintains select internal programs in addition to partnered development:
The company's platform has potential applications in:
Regenxbio's technology is being applied to Parkinson's disease through several partnered programs:
AAV gene therapy approaches for AD include:
Gene therapy for ALS targets:
Regenxbio operates a state-of-the-art GMP manufacturing facility:
The company has established standardized processes enabling rapid transition from discovery to clinical manufacturing.
Regenxbio operates in the AAV gene therapy space:
| Company | Technology | Focus | Status |
|---|---|---|---|
| Spark Therapeutics (Roche) | AAV platform | Ophthalmology, hemophilia | Commercial |
| AveXis (Novartis) | AAV9 | SMA | Commercial |
| Ultragenyx | AAV gene therapy | Rare diseases | Clinical |
| LogicBio | AAV platform | Pediatric disease | Clinical |
| Regenxbio | NAV platform | Multiple (partnered) | Various |
Regenxbio differentiates through:
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $52M | $58M |
| Net Income | -$85M | -$75M |
| Cash | $280M | $350M |
| R&D | $95M | $90M |
Regenxbio generates revenue through:
Regenxbio's strategic priorities include: